BioGx specializes in the development of advanced molecular diagnostics technologies, particularly focusing on Sample-Ready™ PCR assays. Their innovative approach allows for direct sample testing without the need for extraction reagents, simplifying the process and enhancing efficiency. The Xfree™ product line includes assays for various pathogens, such as the Monkeypox virus, HSV-1, HSV-2, and COVID-19, among others. These assays are designed to be compatible with multiple platforms, enabling laboratories to customize their diagnostic capabilities easily. The technology is particularly notable for its lyophilized format, which allows for long-term storage and transport at room temperature, making it accessible for labs with varying levels of infrastructure.

In addition to infectious disease testing, BioGx has established a strong presence in food safety, water quality, and pharmaceutical quality control. Their reagents are tailored for detecting contaminants in cattle feed, shellfish, and drinking water, among other applications. The company’s focus on regulatory compliance is evident, as their products are utilized in official methods by government laboratories, including the US FDA. BioGx's commitment to innovation is reflected in their continuous development of new reagents and their ability to customize formulations to meet specific customer needs, ensuring high performance and sensitivity across diverse testing environments.

United States

BioGX develops molecular products and provides partner-specified formulation and manufacturing services for molecular reagents on a platform of a partner’s choice. The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms.BioGX SARS-CoV-2 Reagents for the BD MAX System - EUA 4/2020

BioGx

Company Details